Literature DB >> 19422216

Robust NMR screening for lead compounds using tryptophan-containing proteins.

Michal Bista1, Kaja Kowalska, Weronika Janczyk, Alexander Dömling, Tad A Holak.   

Abstract

NMR-based drug screening methods provide the most reliable characterization of binding propensities of ligands to their target proteins. Unique to NMR is its capability to detect weak microM-mM bindings. NMR assays are, however, one of the least effective methods in terms of the amount of protein required and the time needed for acquiring NMR experiments. We have recently described a time efficient 1D proton NMR assay for studying the effect of antagonists on protein-protein interactions. The method, named AIDA-NMR (for Antagonist Induced Dissociation Assay-NMR), can provide information on whether an antagonist of a protein-protein interaction is strong enough to dissociate the complex and, in addition, whether its interaction is through denaturation, precipitation, or release of a protein in its functional folded state. AIDA requires a large protein fragment (larger than ca. 30 kDa) to bind to a small reporter protein (smaller than ca.12 kDa). Here, we present an extension of this method, named SEI AIDA (SEI, for Selective Excitation-Inversion). The SEI AIDA uses tryptophan-bearing proteins, and by selectively exciting only the proton NMR signals of the (N)H(epsilon) indole side chains of tryptophans, the acquisition time of the AIDA experiment can be reduced by an order of magnitude relative to the corresponding 1D AIDA that uses hard pulses. Thus, at 600 MHz, the (N)H(epsilon) signal of a 35 microM protein complex can be acquired in only 2.5 min, making the SEI AIDA suitable for high-throughput screening pipelines in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422216     DOI: 10.1021/ja901863h

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  12 in total

1.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

2.  Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators.

Authors:  Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-13       Impact factor: 7.038

3.  Transient protein states in designing inhibitors of the MDM2-p53 interaction.

Authors:  Michal Bista; Siglinde Wolf; Kareem Khoury; Kaja Kowalska; Yijun Huang; Ewa Wrona; Marcelino Arciniega; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Structure       Date:  2013-10-24       Impact factor: 5.006

4.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

5.  Extrinsic Tryptophans as NMR Probes of Allosteric Coupling in Membrane Proteins: Application to the A2A Adenosine Receptor.

Authors:  Matthew T Eddy; Zhan-Guo Gao; Philip Mannes; Nilkanth Patel; Kenneth A Jacobson; Vsevolod Katritch; Raymond C Stevens; Kurt Wüthrich
Journal:  J Am Chem Soc       Date:  2018-06-20       Impact factor: 15.419

6.  Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.

Authors:  Wei Wang; Haiping Cao; Siglinde Wolf; Miguel S Camacho-Horvitz; Tad A Holak; Alexander Dömling
Journal:  Bioorg Med Chem       Date:  2012-06-20       Impact factor: 3.641

7.  1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.

Authors:  Yijun Huang; Siglinde Wolf; Michal Bista; Lidio Meireles; Carlos Camacho; Tad A Holak; Alexander Dömling
Journal:  Chem Biol Drug Des       Date:  2010-05-18       Impact factor: 2.817

8.  Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Authors:  Yijun Huang; Siglinde Wolf; Barbara Beck; Lisa-Maria Köhler; Kareem Khoury; Grzegorz M Popowicz; Sayed K Goda; Marion Subklewe; Aleksandra Twarda; Tad A Holak; Alexander Dömling
Journal:  ACS Chem Biol       Date:  2014-01-17       Impact factor: 5.100

9.  Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor.

Authors:  André Boltjes; Yijun Huang; Rob van de Velde; Laurie Rijkee; Siglinde Wolf; James Gaugler; Katarzyna Lesniak; Katarzyna Guzik; Tad A Holak; Alexander Dömling
Journal:  ACS Comb Sci       Date:  2014-07-11       Impact factor: 3.784

10.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).

Authors:  Krzysztof M Zak; Przemyslaw Grudnik; Katarzyna Guzik; Bartosz J Zieba; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.